The unique approach in WOUNDCOM is the use of molecules derived from human collagen VI and their combination with a biomembrane. Our product acts locally in a wound bed mimicking natural collagen VI upregulation in the healing process and avoids systemic exposure, paving the way for a favorable safety profile. Our compounds proved more effective in combating bacterial wound infections and with no cytotoxic side effects.
This unique solution creates a new category of wound care products and addresses a new market segment of interactive biomembranes on the global market. Our solution can be used in acute as well as in chronic wounds. Faster and more efficient treatment of acute and chronic wounds implies several benefits for patients and medical professionals and will increase demand for WOUNDCOM in hospitals and clinics.
Moreover, as our invention has defined antibacterial effects against all bacteria tested so far, including multidrug resistant bacteria, it will combat multidrug resistance (listed by the WHO as one of the biggest threats to global health).
WOUNDCOM has the potential to substantially reduce costs associated with lengthy healing processes and treatment of infections acquired through medical conditions and in surgical procedures. Colzyx has built strong partnership with an established biomaterial/wound management company. The companies are currently discussing continued collaboration associated with product launch to address the unmet needs of patients and healthcare in the wound management segment.